[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Herlev Hospital\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":495},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,18,0,[8,41,64,94,123,152,184,210,228,259,285,314,348,378,400,422,444,471],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":17,"sex":18,"minAge":4,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":30,"lastUpdatePostDateStruct":31,"startDateStruct":34,"completionDateStruct":36,"leadSponsor":38,"locationsCount":4},"100439630","dermoscopy-augmented-histology-trial-a-randomized-controlled-trial-100439630",false,"NCT05004792","Dermoscopy Augmented Histology Trial, a Randomized Controlled Trial","Correlation Between Online Case-based Training of Pathologists in Dermoscopic Images and Diagnostic Accuracy in Histopathological Interpretation of Skin Lesions Suspicious of Melanoma","DAHT-RCT","Inclusion Criteria:\n\n* Pathologists are required to evaluate melanocytic lesions routinely\n* Doctors must be registered authorized health personnel\n* Access to a smartphone\u002Ftablet\u002Fcomputer with internet\n\nExclusion Criteria:\n\n\\- Assessment of less than 30 DAHT cases",true,"ALL",{"count":20,"type":21},258,"ESTIMATED","INTERVENTIONAL",[24],"NA","Pathologists provide the current gold standard in skin lesion diagnostics, most often primarily based on the interpretation of histological slides. Still, it has been suggested that pathologists' diagnostic accuracy and confidence could be improved if they gained access to additional clinical information and in-vivo clinical and dermoscopic images of melanocytic tumors. This study examines the effect of digital training for pathologists in interpreting dermoscopic and clinical skin tumor images.\n\nThis study aims to evaluate the impact of dermoscopy training on pathologists' assessment of melanoma-suspected skin lesions.\n\nData collection of DAHT cases: Department of plastic surgery, Herlev hospital, year 2020-2021,\n\nDAHT platform: Made in 2021-2023 by Melatech,\n\nConsensus agreement: Four dermatopathologists assess all DAHT cases, year 2023-2024\n\nEnrollment of pathologists: Randomization and assessment DAHT cases, year 2026.",[27,28],"Melanoma","Pigmented Lesions","NOT_YET_RECRUITING","2026-06-24",{"date":32,"type":33},"2026-06-25","ACTUAL",{"date":35,"type":21},"2026-08-13",{"date":37,"type":21},"2027-12-13",{"name":39,"class":40},"Herlev Hospital","OTHER",{"id":42,"slug":43,"hasResults":11,"nctId":44,"briefTitle":45,"officialTitle":46,"acronym":47,"eligibilityCriteria":48,"healthyVolunteers":11,"sex":18,"minAge":49,"maxAge":4,"enrollmentInfo":50,"targetDuration":4,"studyType":22,"phases":52,"briefSummary":53,"conditions":54,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":56,"lastUpdatePostDateStruct":57,"startDateStruct":59,"completionDateStruct":61,"leadSponsor":63,"locationsCount":4},"100644538","zinc-supplementation-and-inflammation-in-older-medical-patients-100644538","NCT07672132","Zinc Supplementation and Inflammation in Older Medical Patients","ZOOM IN Study: Micronutrient Deficiencies and Effect of Zinc Supplementation on Inflammation and Occurrence of Infections in Older Medical Patients (ZOOM) - A Sub-study of a Cluster Randomized Trial","ZOOM-IN","Inclusion Criteria:\n\n* above 65 years old included in ZOOM out ( clinical trials no: NCT07367412)\n* admittet at the medical emergency department Herlev Hospital\n\nExclusion Criteria:\n\n* Patients receiving zinc supplements (\\>10 mg daily) at time of inclusion\n* Patients with terminal illness (life expectancy \\\u003C 6 months, estimated by Clinical Frailty Scale ≥8)\n* Patients receiving parenteral nutrition (partial or complete)\n* Patients treated with hemodialysis or peritoneal dialysis\n* Patients known with severe dementia\n* Patients who do not understand Danish and patients with temporary civil person registration numbers (CPR)","65 Years",{"count":51,"type":21},220,[24],"The hypothesis is that a daily supplement of 22 mg of zinc over 12 months can reduce in-flammatory biomarkers in acutely hospitalized older adults aged ≥ 65 years.\n\nThe aims are to determine, in acutely hospitalized older adults aged ≥ 65 years, if a daily supplement of 22 mg of zinc over 12 months compared to control can decrease inflammato-ry biomarkers, reduce symptoms of self-reported infection, reduce readmission and mortali-ty, increase QoL, increase physical performance, investigate potential adverse events to zinc supplement, and the changes in inflammatory biomarkers. It will also be studied if albumin-corrected zinc in plasma is a more accurate method for assessing zinc status than ordinary plasma zinc.",[55],"Older Medical Patients","2026-06-23",{"date":58,"type":33},"2026-06-26",{"date":60,"type":21},"2026-06-02",{"date":62,"type":21},"2028-05-31",{"name":39,"class":40},{"id":65,"slug":66,"hasResults":11,"nctId":67,"briefTitle":68,"officialTitle":69,"acronym":70,"eligibilityCriteria":71,"healthyVolunteers":11,"sex":18,"minAge":49,"maxAge":4,"enrollmentInfo":72,"targetDuration":4,"studyType":22,"phases":74,"briefSummary":75,"conditions":76,"keywords":79,"overallStatus":84,"whyStopped":4,"lastUpdateSubmitDate":85,"lastUpdatePostDateStruct":86,"startDateStruct":88,"completionDateStruct":90,"leadSponsor":92,"locationsCount":93},"100621191","zinc-supplementation-and-infections-in-older-medical-patients-100621191","NCT07367412","Zinc Supplementation and Infections in Older Medical Patients","Effect of Zinc Supplementation on Occurrence of Infections in Older Medical Patients (ZOOM) - a Cluster Randomized Controlled Trial (ZOOM OUT).","ZOOM OUT","Inclusion Criteria:\n\n* All medical patients aged ≥ 65 years assessed at the Medical Emergency Department, Herlev Hospital\n\nExclusion Criteria:\n\n* Self-supplementing with zinc at time of assessment (\\> 10 mg zinc\u002Fday)\n* Terminal illness (life expectancy \\\u003C 6 months, estimated by Clinical Frailty Scale ≥8)\n* Patients receiving parenteral nutrition (partial or complete)\n* Patients treated with hemodialysis or peritoneal dialysis\n* Patients know with known severe dementia\n* Patients who do not understand Danish and patients with temporary civil person registration numbers (CPR)",{"count":73,"type":21},8000,[24],"The goal of this clinical trial is to learn about the effect of zinc supplementation once daily for 12 months in older acute medical patients. The main question it aims to answer is:\n\n• Can daily zinc supplementation for 12 months increase Days Alive and Out of Hospital (DAOH)? Researchers will compare zinc supplementation to a control group, a group who do not receive zinc supplementation, to see if zinc supplementation can increase Days Alive and Out of Hospital, reduce antibiotic use, readmissions and mortality.\n\nParticipants will take 22 mg zinc supplementation once daily for 12 months or not.\n\nThe researchers will draw data on readmissions, antibiotic use and mortality during the 12 months follow-up period.",[77,78],"Older Adults (65 Years and Older)","Medical Patients in the Emergency Department",[80,81,82,83],"Older adults","Infections","Days alive and out of hospital","Zinc supplementation","RECRUITING","2026-05-28",{"date":87,"type":33},"2026-05-29",{"date":89,"type":33},"2026-02-01",{"date":91,"type":21},"2028-03-15",{"name":39,"class":40},2,{"id":95,"slug":96,"hasResults":11,"nctId":97,"briefTitle":98,"officialTitle":99,"acronym":100,"eligibilityCriteria":101,"healthyVolunteers":11,"sex":18,"minAge":102,"maxAge":4,"enrollmentInfo":103,"targetDuration":4,"studyType":22,"phases":105,"briefSummary":106,"conditions":107,"keywords":109,"overallStatus":84,"whyStopped":4,"lastUpdateSubmitDate":114,"lastUpdatePostDateStruct":115,"startDateStruct":117,"completionDateStruct":119,"leadSponsor":121,"locationsCount":122},"100606105","the-effect-of-regulation-of-parathyroid-hormone-in-patients-with-chronic-kidney-disease-to-investigate-the-change-in-bone-mineral-density-100606105","NCT07171216","The Effect of REgulation of PArathyroId hoRmone in Patients With Chronic Kidney Disease to Investigate the Change in Bone Mineral Density","The Effect of REgulation of PArathyroId hoRmone in Patients With Chronic Kidney Disease to Investigate the Change in Bone Mineral Density (Biskjoldbruskkirtelhormon og knogletæthed Hos Patienter Med Kronisk Nyresygdom)","REPAIR-CKD","Inclusion Criteria:\n\n1. ≥50 years of age at screening\n2. CKD G4-5nonD (eGFR \\\u003C 30 mL\u002Fmin\u002F1.73m2) based on local laboratory assessment of serum creatinine and eGFR estimated by the CKD-EPI formula)\n3. Plasma PTH \\> upper normal limit of local laboratory reference range (\\> 8,5µmol\u002FL) and\u002For treated with active vitamin D (Alphacalcidol) or calcimetics (Cinacalcet) initially\n4. Written informed consent\n\nExclusion Criteria:\n\n1. Patients who have received a kidney transplant\n2. Patients receiving treatment with specific anti-osteoporosis medication (denosumab\u002Fbisphosphonates) (because of the profound effect on calcium\u002Fphosphate fluxes and BMD)","50 Years",{"count":104,"type":21},70,[24],"The prevalence of chronic kidney disease (CKD) in the adult population is estimated to 10%. CKD increases risk of bone fractures, cardiovascular disease and death. The main role of parathyroid hormone (PTH) is to regulate mineral metabolism, including the calcium and phosphate homeostasis. PTH increases as the kidney function declines, and at end stage kidney disease almost all patients have disturbances in the mineral metabolism. Decreasing bone mineral density is associated with risk of fracture, both in background population and in patients with CKD.\n\nFor decades, treatment with activated vitamin D, phosphate binders, and calcium supplements has been used for patients with chronic kidney disease and elevated parathyroid hormone, but treatment targets have varied greatly over the years, reflecting the lack of randomized clinical trials with clinical important end points.\n\nThe purpose of The REPAIR-CKD trial is to determine if treatment of hyperparathyroidism improves the bone mineral density in patients with chronic kidney disease.\n\nDuring this trial it will also be evaluated if it is feasible to obtain a difference in PTH levels when targeting two different levels of PTH.\n\nFurther this trial will explore if a difference in PTH influences on arterial stiffness, muscle mass, muscle function, bone histology and health related quality of life.",[108],"Chronic Kidney Disease Mineral and Bone Disorder",[110,111,112,113],"parathyroid hormone","chronic kidney disease","randomized clinical trial","Activated vitamin D","2026-01-05",{"date":116,"type":33},"2026-01-06",{"date":118,"type":33},"2025-11-20",{"date":120,"type":21},"2027-09-01",{"name":39,"class":40},1,{"id":124,"slug":125,"hasResults":11,"nctId":126,"briefTitle":127,"officialTitle":128,"acronym":4,"eligibilityCriteria":129,"healthyVolunteers":11,"sex":18,"minAge":130,"maxAge":4,"enrollmentInfo":131,"targetDuration":133,"studyType":134,"phases":4,"briefSummary":135,"conditions":136,"keywords":139,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":144,"lastUpdatePostDateStruct":145,"startDateStruct":147,"completionDateStruct":149,"leadSponsor":151,"locationsCount":4},"100607784","the-cph-mbd-cohort-100607784","NCT07193056","The CPH-MBD Cohort","Chronic Kidney Disease -Mineral and Bone Disorder, The CPH-MBD Cohort","Inclusion Criteria:\n\n* Age ≥18 years\n* CKD stage 4-5nonD (eGFR ≤ 29 ml\u002Fmin) according to KDIGO (Kidney Disease Improving Global Outcome) definition\n\nExclusion Criteria:\n\n* None","18 Years",{"count":132,"type":21},1000,"25 Years","OBSERVATIONAL","Persons with chronic kidney disease (CKD) have a 3-fold increased risk of bone fracture and a 10-fold increased risk of cardiovascular disease than the general population. These increased risks are related to the disturbances in the mineral metabolism, and this clinical entity is termed Chronic Kidney Disease - Mineral and Bone Disorder (CKD-MBD).\n\nThe overall aim of the present project is to explore factors that may predict or associate with the development of bone and cardiovascular disease in patients with CKD and hopefully provide insight into underlying mechanisms and pathophysiological pathways for future treatment and prevention.\n\nIn a sub study investigators aim to explore the calcium and phosphate balance in patients with CKD and describe how these associate with each other as well as with kidney function (eGFR).",[108,137,138],"Chronic Kidney Disease (CKD)","Bone Markers",[140,110,141,142,143],"bone markers","fracture risk","bone turnover","dietary assessment","2025-12-24",{"date":146,"type":33},"2025-12-31",{"date":148,"type":21},"2025-12",{"date":150,"type":21},"2055-01",{"name":39,"class":40},{"id":153,"slug":154,"hasResults":11,"nctId":155,"briefTitle":156,"officialTitle":157,"acronym":158,"eligibilityCriteria":159,"healthyVolunteers":11,"sex":18,"minAge":130,"maxAge":160,"enrollmentInfo":161,"targetDuration":4,"studyType":134,"phases":4,"briefSummary":163,"conditions":164,"keywords":172,"overallStatus":84,"whyStopped":4,"lastUpdateSubmitDate":176,"lastUpdatePostDateStruct":177,"startDateStruct":178,"completionDateStruct":180,"leadSponsor":182,"locationsCount":183},"100432824","diabetic-nephropathy-in-people-with-diabetes-prevalence-and-predictive-factors-100432824","NCT04916132","Diabetic Nephropathy in People With Diabetes. Prevalence and Predictive Factors","Biopsy-proven Diabetic Nephropathy in People With Type 2 Diabetes. Prevalence and Predictive Factors","PRIMETIME2","Inclusion Criteria:\n\n* Age ≥ 18 years\n* Written informed consent\n* Diagnosis with T2DM according to the American diabetes Association (20)\n* eGFR \\>30 mL\u002Fmin\u002F1.73 m2 (maximum six months old)\n* urine-albumin\u002Fcreatinine-ratio (uACR) \\> 700 mg\u002Fg or 24 hours urine albumin \\>700 mg on more than one measurement\n\nExclusion Criteria:\n\n* Signs of acute kidney failure according to the KDIGO classification (21) at the time for kidney biopsy or the last 6 months before kidney biopsy\n* Factors that increases the risk of complications due to kidney biopsy:\n\n  * Hemoglobin \\\u003C 6 mmol\u002FL\n  * INR \\>1,4 at the time for biopsy\n  * Platelet count \\\u003C 100 x 109\u002Fl\n  * Uncontrolled high blood pressure (defined as systolic blood pressure \\> 160 mmHg and\u002For diastolic blood pressure \\> 100 mmHg)\n  * Only one functioning kidney\n  * Evidence of urinary tract obstruction or hydronephrosis at the time of biopsy\n  * Multiple bilateral kidney cysts\n  * Kidney infection, peri-renal infection, or cutaneous infection that overlies the kidney at time for biopsy\n  * Unwilling to receive blood transfusion\n  * Unable to lie flat in bed six hours after biopsy\n  * Any other contra-indications for percutaneous kidney biopsy according to local clinical guidelines\n* Unable to understand written and oral information\n* Kidney transplant recipient\n* Previous medical kidney biopsy\n* Women who are pregnant or planning to become pregnant before the kidney biopsy is performed\n* Treatment with Marcoumar (all other anticoagulants are accepted)\n* High thromboembolic risk combined with held in anticoagulation therapy according to the report \"Perioperative regulation of antithrombotic treatment\" (PRAB) (22)\n\n  * mechanical heart valve\n  * atrial fibrillation AND CHA2DS2-VASc\\> 5 and\u002For stroke within the last three months\n  * recurrent venous thromboembolism OR venous thromboembolism within the last three months\n  * less than 6 weeks after uncomplicated Acute Coronary Syndrome (ACS) with or without revascularization (Percutaneous Coronary Intervention (PCI)) with Bare Metal Stents (BMS) or Coronary Artery Bypass Grafting (CABG))\n  * less than 3 months after uncomplicated ACS with revascularization (PCI with Drug Eluting Stent (DES))\n  * less than 9-12 months after complicated ACS (e.g. reinfarction or stent thrombosis)\n  * less than 1 month after revascularization in individuals with stable Coronary Artery Disease (CAD) (PCI with BMS or CABG)\n  * less than 3 months after revascularization in individuals with stable CAD (PCI with DES)\n  * less than 3 months after stroke, or Transient Ischemic Attack (TIA)\n* Inability to withdraw nonsteroidal anti-inflammatory drugs (NSAID) 7 days before biopsy\n\nIf a participant meets one or more exclusion criteria, that are reversible, the participant can be rescreened later on, to evaluate whether or not the participant now is qualified for participation.","120 Years",{"count":162,"type":21},300,"a prospective, observational, multi-center study with a cohort of 300 patients with Type 2 diabetes and macroalbuminuria. Prospectively we will collect kidney biopsies and analyse the transciptome of the kidney tissue and other biomarkers from blood, faeces, urine, proteomic- and metabolomic profiles and DNA-variants. Thereby we hope to be able to discover molecular and clinical profiles, that can help us in the diagnosis of DKD, and to identify different risks of progression that can benefit from different forms of personalized treatment.",[165,166,167,168,169,170,171],"Chronic Kidney Diseases","Albuminuria","Diabetic Kidney Disease","Diabetic Nephropathies","Diabetes type2","Molecular Sequence Variation","Kidney Biopsy",[173,174,175],"diabetic nephropaty","precision medicine","kidney biopsy","2025-12-17",{"date":144,"type":33},{"date":179,"type":33},"2021-08-10",{"date":181,"type":21},"2043-12-31",{"name":39,"class":40},13,{"id":185,"slug":186,"hasResults":11,"nctId":187,"briefTitle":188,"officialTitle":189,"acronym":190,"eligibilityCriteria":191,"healthyVolunteers":11,"sex":18,"minAge":130,"maxAge":4,"enrollmentInfo":192,"targetDuration":4,"studyType":134,"phases":4,"briefSummary":194,"conditions":195,"keywords":4,"overallStatus":84,"whyStopped":4,"lastUpdateSubmitDate":202,"lastUpdatePostDateStruct":203,"startDateStruct":205,"completionDateStruct":207,"leadSponsor":209,"locationsCount":122},"100613868","endoscopic-ultrasound-guided-radiofrequency-ablation-for-upper-gastrointestinal-tract-lesions-100613868","NCT07272187","Endoscopic Ultrasound-guided Radiofrequency Ablation for Upper Gastrointestinal Tract Lesions","Endoscopic Ultrasound-guided Radiofrequency Ablation for Upper Gastrointestinal Tract Lesions - a Prospective Study","EURAGIL","Inclusion Criteria:\n\n* Patients with one or more lesions amendable to undergo EUS-RFA\n\n  * Insulinomas ≤ 25 mm confirmed by a 72-h fasting test, cross-sectional scanning, and a biopsy with low Ki67 index (\\\u003C10%)\n  * Non-functional pNEN lesions between 10-20 mm and growing, confirmed by a biopsy with low Ki67 index (\\\u003C10%), or larger pNEN lesions in patients who are not candidates for surgical treatment\n  * Unilateral APA with benign characteristics on non-contrast enhanced CT located in the left adrenal and confirmed lateralization on AVS\n\n    * Adult habile patients\n    * Signed informed consent\n\nExclusion Criteria:\n\n* Severe multimorbidity (ASA score ≥ IV or ECOG performance score ≥ 4)\n\n  * Uncorrected coagulopathy (INR \\>1.8 or thrombocyte count \\\u003C 50 mia\u002FL)\n  * Pregnancy\n  * Metastatic malignancy with expected remaining life expectancy \\\u003C 3 years\n  * Stenosis in upper GI tract or altered anatomy (e.g. previous gastrectomy) preventing the passage of an echoendoscope",{"count":193,"type":21},138,"The goal of this observational study is to evaluate the long-term clinical effectiveness of EUS-RFA and quality of life in patients with pancreatic or adrenal tumors recieving EUS-RFA.\n\nPrimary Objectives:\n\n* Clinical effectiveness: To evaluate the proportion of included patients who show doc-umented improvement in their clinical symptoms and biochemical parameters (blood test results) over time.\n* Patient satisfaction: To assess patient satisfaction with the procedure and subsequent disease-related quality of life, measured using validated questionnaires.\n\nSecondary Objectives:\n\n* Safety: To determine the proportion of treated patients who experience complications, as defined by the AGREE classification, within 30 days after the procedure.\n* Technical success: To assess the proportion of included patients in whom the EUS-RFA procedure can be successfully completed.\n\nExploratory Objectives:\n\n• To identify factors associated with adverse events and factors related to clinical success or lack there of.\n\nThe study is observational. All participant will receive EUS-RFA as part of their standard clinical care.\n\nParticipants will:\n\n* Undergo EUS-RFA, in which a fine needle is guided into the tumor using an endo-scope and ultrasound imaging. Radiofrequency energy is applied through the needle to heat and destroy tumor cells while protecting the surrounding tissue.\n* Have follow-up visits including blood tests, imaging scans, and clinical evaluations at regular intervals for up to 5 years after treatment.\n* Complete validated questionnaires about satisfaction and quality of life.\n\nThe study will include approximately 138 patients recruited between 2025 and 2035 from two Danish hospital departments (Herlev and Gentofte Hospital and Rigshospitalet). Data collection will continue until 2040 to assess long-term outcomes.\n\nThis study may help determine whether EUS-RFA can serve as a safe and effective alternative to traditional surgery for selected patients with small hormone-producing or benign tumors in the pancreas or adrenal glands, potentially reducing surgical risks and improving recovery and quality of life.",[196,197,198,199,200,201],"Insulinoma; Pancreas","MEN1","NETs","Radiofrequency Ablation","Endoscopic Ultrasound (EUS)","Conn Syndrome","2025-11-26",{"date":204,"type":33},"2025-12-09",{"date":206,"type":33},"2025-11-01",{"date":208,"type":21},"2041-12-31",{"name":39,"class":40},{"id":211,"slug":212,"hasResults":11,"nctId":213,"briefTitle":214,"officialTitle":214,"acronym":215,"eligibilityCriteria":216,"healthyVolunteers":11,"sex":18,"minAge":130,"maxAge":4,"enrollmentInfo":217,"targetDuration":4,"studyType":134,"phases":4,"briefSummary":218,"conditions":219,"keywords":4,"overallStatus":84,"whyStopped":4,"lastUpdateSubmitDate":222,"lastUpdatePostDateStruct":223,"startDateStruct":224,"completionDateStruct":225,"leadSponsor":227,"locationsCount":122},"100612170","the-role-of-microbiota-in-pancreatic-cancer-and-precursor-lesions-100612170","NCT07250100","The Role of Microbiota in Pancreatic Cancer and Precursor Lesions","MICROPAC","Inclusion Criteria:\n\n* Patients with a suspected lesion (solid\u002Fcystic) in the pancreas undergoing diagnostic or therapeutic endoscopic procedure\n* Age of 18 years or above\n* Signed informed consent form\n\nExclusion Criteria:\n\n* Contraindications for endoscopic or surgical procedure, such as uncorrected coagulopathy",{"count":162,"type":21},"This is a prospective observational study aiming to investigate the microbiome in patients suspected of having pancreatic cancer. The purpose is to enhance diagnostic accuracy by developing screening protocols for high-risk individuals, identifying specific microbial biomarkers, and improving prognostic criteria to optimize treatment response.\n\nParticipants will be asked to complete a questionnaire, provide oral and fecal swabs, and-if clinically indicated-1-2 pancreatic biopsies will be collected.",[220,221],"Pancreatic Cancer","Microbiome","2025-11-18",{"date":202,"type":33},{"date":206,"type":33},{"date":226,"type":21},"2037-12",{"name":39,"class":40},{"id":229,"slug":230,"hasResults":11,"nctId":231,"briefTitle":232,"officialTitle":233,"acronym":234,"eligibilityCriteria":235,"healthyVolunteers":11,"sex":236,"minAge":130,"maxAge":237,"enrollmentInfo":238,"targetDuration":4,"studyType":22,"phases":240,"briefSummary":241,"conditions":242,"keywords":245,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":251,"lastUpdatePostDateStruct":252,"startDateStruct":254,"completionDateStruct":256,"leadSponsor":258,"locationsCount":4},"100604017","tape-application-protocol-for-enhanced-scars-100604017","NCT07144046","Tape Application Protocol for Enhanced Scars","The Effect of Long-term Micropore Coverage on Cosmetic Outcomes After Mastectomy","TAPES","Inclusion Criteria:\n\n* Women undergoing mastectomi without primary recontruction\n* BMI between 18-5 and 35\n* Age between 18 and 80\n\nExclusion Criteria:\n\n* Known bandaid allergy\n* In need of Mepilex Border OP after surgery\n* Concurrent treatment with systemic steroid treatment or other immunosuppresants\n* Post surgical haematoma that requires surgical intervention\n* Known tendency to kelloid or hypertrophic scar formation","FEMALE","80 Years",{"count":239,"type":21},90,[24],"What is the purpose of this study? The Investigators want to find out whether applying Micropore surgical tape to the medial half of the mastectomy scar for 3 months helps improve its appearance after 12 months, compared to no intervention.\n\nWhy is this study important? Scars can cause discomfort and affect how people feel about their bodies. The tape is thought to reduce stress on healing skin and possibly lead to a better-looking scar. But The Investigators need strong evidence to know whether it really helps.\n\nHow will the study be done?\n\nThis is a randomized, observer-blinded trial.\n\nWomen having mastectomy are randomly assigned to either receive the tape on half their scar or receive no tape.\n\nA plastic surgeon and a breast surgeon-who do not know which side had tape-will evaluate wounds using photos after 3 and 12 months.\n\nPatients will also rate their scars using a questionnaire (POSAS), giving their personal view on color, thickness, stiffness, and symptoms like itch or pain.\n\nWhat else are The Investigators looking at?\n\nThe Investigators will examine whether the treated half of the scar looks better than the untreated half within the same woman-this helps control for individual skin differences.\n\nThe Investigators will also compare treated versus untreated areas across different women to see if there is a consistent benefit.\n\nIf the untaped half of scars looks different from control scars, this may suggest differences between the groups that affect results.\n\nWhat will this study reveal? It will show whether using the tape improves cosmetic outcomes after mastectomy, and whether patients and clinicians agree on how scars heal. The findings may guide better post-surgery care to reduce scars and improve confidence and quality of life.",[243,244],"Scar Improvement","Cosmetic Outcome",[246,247,248,249,250],"Cosmetic Scar Evaluation","Long term wound dressing","Scar formation","Mastectomy","Breast Cancer","2025-08-20",{"date":253,"type":33},"2025-08-27",{"date":255,"type":21},"2025-09-01",{"date":257,"type":21},"2028-09-01",{"name":39,"class":40},{"id":260,"slug":261,"hasResults":11,"nctId":262,"briefTitle":263,"officialTitle":264,"acronym":4,"eligibilityCriteria":265,"healthyVolunteers":11,"sex":266,"minAge":130,"maxAge":4,"enrollmentInfo":267,"targetDuration":4,"studyType":22,"phases":269,"briefSummary":270,"conditions":271,"keywords":273,"overallStatus":84,"whyStopped":4,"lastUpdateSubmitDate":278,"lastUpdatePostDateStruct":279,"startDateStruct":281,"completionDateStruct":283,"leadSponsor":284,"locationsCount":122},"100602011","platelet-rich-plasma-for-peyronies-disease-100602011","NCT07117955","Platelet-Rich Plasma for Peyronie's Disease","Treatment of Peyronie's Disease With Platelet-Rich Plasma: A Randomized, Double-blind, Placebo-controlled Clinical Trial","Inclusion Criteria:\n\n* 18 years or older\n* Be able to provide written informed consent\n* Diagnosis of PD without active pain and without progressive curvature over the past 3 months (fibrotic phase).\n* Penile curvature of 30-95 degrees\n* Clearly palpable penile plaque\n\nExclusion Criteria:\n\n* Erectile Dysfunction unresponsive to on-demand PDE5 inhibitors\n* Hourglass malformation\n* Severely calcified plaques where injection is considered unfeasible\n* Intrapenile plaque\n* History of priapism.\n* History of penile fracture.\n* Previous treatment for PD with injections and\u002For surgery.\n* Antithrombotic therapy associated with a high risk of bleeding","MALE",{"count":268,"type":21},84,[24],"The purpose of this clinical trial is to evaluate the effects of Platelet-Rich Plasma (PRP) intralesional injections in men affected by Peyronie's disease (PD) in the fibrotic phase.",[272],"Peyronies Disease",[274,275,276,277],"Andrology","Platelet-Rich Plasma","Penile induration","PRP","2025-08-11",{"date":280,"type":33},"2025-08-14",{"date":282,"type":21},"2025-09-20",{"date":257,"type":21},{"name":39,"class":40},{"id":286,"slug":287,"hasResults":11,"nctId":288,"briefTitle":289,"officialTitle":289,"acronym":290,"eligibilityCriteria":291,"healthyVolunteers":17,"sex":236,"minAge":130,"maxAge":4,"enrollmentInfo":292,"targetDuration":4,"studyType":134,"phases":4,"briefSummary":294,"conditions":295,"keywords":303,"overallStatus":84,"whyStopped":4,"lastUpdateSubmitDate":306,"lastUpdatePostDateStruct":307,"startDateStruct":309,"completionDateStruct":311,"leadSponsor":313,"locationsCount":122},"100580954","birth--breastfeeding-support-study-100580954","NCT06844019","Birth & Breastfeeding Support Study","BABSS","Inclusion Criteria: 18 years, intention to breastfeed, single gestation, reads and understands Danish -\n\nExclusion Criteria: Twin gestation, less than 18 years, no intention to breastfeed, does not read and understand Danish\n\n\\-",{"count":293,"type":21},1628,"The goal of this observational study is to learn about the effects of birth practices such as cesarean section and vacuum assisted birth and diseases such as gestational diabetes and preeclampsia on exclusive breastfeeding. The main question it aims to answer is:\n\n• Does cesarean section, vacuum assisted birth, gestational diabetes and preeclampsia affect exclusive breastfeeding three months after birth? Participants answer eight online survey questions. One survey is distributed before birth and the remaining seven surveys are distributed after birth at three, seven and four-teen days, as well as one, three, six and twelve months after birth.",[296,297,298,299,300,301,302],"Breastfeeding","Breastfeeding Initiation","Breastfeeding Duration","Birth","Birth Practices","Gestational Diabetes Mellitus (GDM)","Preeclampsia",[304,305],"Birth, birth practices, gestational diabetes, preeclampsia","breastfeeding","2025-05-22",{"date":308,"type":33},"2025-05-28",{"date":310,"type":33},"2025-01-06",{"date":312,"type":21},"2028-01",{"name":39,"class":40},{"id":315,"slug":316,"hasResults":11,"nctId":317,"briefTitle":318,"officialTitle":318,"acronym":319,"eligibilityCriteria":320,"healthyVolunteers":17,"sex":18,"minAge":130,"maxAge":4,"enrollmentInfo":321,"targetDuration":4,"studyType":22,"phases":323,"briefSummary":324,"conditions":325,"keywords":336,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":340,"lastUpdatePostDateStruct":341,"startDateStruct":343,"completionDateStruct":345,"leadSponsor":347,"locationsCount":4},"100590960","patient--and-family-centred-care-in-the-adult-intensive-care-unit-a-feasibility-study-100590960","NCT06974214","Patient- and Family-centred Care in the Adult Intensive Care Unit: a Feasibility Study","FAM-ICU","Patients are eligible if they are:\n\n* ≥18 years of age.\n* Expected to require ICU admission for at least 48 hours in a mixed surgical and medical ICU for adult critically ill patients.\n\nFamily members are eligible if they are:\n\n* ≥18 years of age.\n* a close family member to a patient-enrolled in the FAM-ICU. A family-member can be blood-related or not. It may be a spouse, relative, partner, or friend as determined by the patient as a close family member.",{"count":322,"type":21},60,[24],"Background: In the intensive care unit (ICU), delirium in patients and long-term mental health challenges in both patients and their family members are highly prevalent. To address these issues, patient- and family-centered care has been recommended to alleviate the burdens associated with critical illness and ICU admission. We have developed the patient- and FAMily-centered care in the adult ICU intervention (FAM-ICU intervention). This multi-component intervention comprises several concrete and manageable components and operationalizing patient- and family-centered care principles in clinical practice. In this protocol, we describe a study aiming to evaluate the feasibility and acceptability of the FAM-ICU intervention in the adult ICU setting, including the feasibility of collecting relevant patient- and family-member outcome data.\n\nReferenc: Bohart et al. 2024. Acta Anaesthesiol Scand\n\n. 2025 Jan;69(1):e14539. doi: 10.1111\u002Faas.14539. Epub 2024 Oct 24. Method: We will conduct a pre-\u002Fpost two-group study design. We plan to recruit 30 adult ICU patients and their close family members at Herlev University Hospital in Denmark. The pre-group (n = 15) will receive usual care and the post-group (n = 15) will receive the FAM-ICU intervention. The FAM-ICU intervention involves interdisciplinary training of the ICU team and a systematic approach to information sharing and consultations with the patients and their family. Feasibility outcomes will include recruitment and retention rates, intervention fidelity, and the feasibility of participant outcome data collection. Acceptability will be assessed through questionnaires and interviews with clinicians, patients, and family members. Data collection is scheduled to begin in January 2025.\n\nDiscussion: This study will assess the feasibility and acceptability when implementing the FAM-ICU intervention and the feasibility of conducting a main trial to investigate its effectiveness on delirium in patients and the mental health of patients and family members. The data from the feasibility study will be used to guide sample size calculations, trial design, and final data collection methods for a subsequent stepped-wedge randomized controlled trial.",[326,327,328,329,330,331,332,333,334,335],"Delirium","Anxiety","Post Intensive Care Unit Syndrome","Post Intensive Care Unit Syndrome Family","Depression","Posttraumatic Stress Disorder (PTSD)","Mortality","Length of ICU Stay","Pain","Satisfaction Survey",[337,338,339],"Patient- and family-centerede care","Feasibility","ICU","2025-05-08",{"date":342,"type":33},"2025-05-15",{"date":344,"type":21},"2025-08-01",{"date":346,"type":21},"2026-08-01",{"name":39,"class":40},{"id":349,"slug":350,"hasResults":11,"nctId":351,"briefTitle":352,"officialTitle":353,"acronym":4,"eligibilityCriteria":354,"healthyVolunteers":11,"sex":18,"minAge":130,"maxAge":4,"enrollmentInfo":355,"targetDuration":4,"studyType":22,"phases":357,"briefSummary":358,"conditions":359,"keywords":363,"overallStatus":84,"whyStopped":4,"lastUpdateSubmitDate":370,"lastUpdatePostDateStruct":371,"startDateStruct":373,"completionDateStruct":375,"leadSponsor":377,"locationsCount":93},"100435051","stroke-school--including-physical-exercise-patient-education-and-individual-follow-up-sessions-100435051","NCT04945174","Stroke School -Including Physical Exercise, Patient Education and Individual Follow-up Sessions","Stroke School - Cross-sectorial Physical Exercise for Patients With Minor Stroke or Non-disabling Stroke","Inclusion Criteria:\n\n* Patients with a minor stroke or TIA without the need of rehabilitation after hospital discharge, but need physical activity in order to prevent cardiovascular diseases\n* Patients spending ≤ 5 hour of leisure time on high-intensity physical activity on weekly basis within the last 3 months\n* Able to speak and read Danish and to provide informed consent\n* Individuals ≥ 18 years of age\n\nExclusion Criteria:\n\n* Previous large-artery stroke or hemorrhagic stroke\n* Unstable cardiac condition, e.g. pacemaker\n* Uncontrolled hypertension (patients not responding adequately to antihypertensive medication when applying treatment according to guidelines)\n* Symptoms or comorbidities not allowing exercise on a stationary bicycle (e.g. claudication)\n* Dyspnoea caused by heart or pulmonary disease (e.g. COPD)\n* Aphasia, or dementia that interferer with understanding the protocol and\u002For physical examinations.\n* Patients diagnosed with dementia at hospital admission (a score ≤23\u002F30 on the Mini-Mental State Examination are not invited into the study)",{"count":356,"type":21},100,[24],"In a randomized controlled trial the effect of 12 weeks of cross-sectorial physical exercise combined with patient education and individual follow-up session is investigated in patients with minor stroke or non-disabling stroke.",[360,361,362],"Minor Stroke","Non-disabling Stroke","Transient Ischemic Attack",[364,365,366,367,368,369],"Minor stroke","Stroke prevention","Physical exercise","Patient education","Cardiorespiratory fitness","Non-disabling stroke","2025-04-29",{"date":372,"type":33},"2025-05-02",{"date":374,"type":33},"2022-06-01",{"date":376,"type":21},"2033-12",{"name":39,"class":40},{"id":379,"slug":380,"hasResults":11,"nctId":381,"briefTitle":382,"officialTitle":383,"acronym":4,"eligibilityCriteria":384,"healthyVolunteers":11,"sex":18,"minAge":130,"maxAge":4,"enrollmentInfo":385,"targetDuration":4,"studyType":134,"phases":4,"briefSummary":387,"conditions":388,"keywords":389,"overallStatus":84,"whyStopped":4,"lastUpdateSubmitDate":392,"lastUpdatePostDateStruct":393,"startDateStruct":395,"completionDateStruct":397,"leadSponsor":399,"locationsCount":122},"100454345","pharmacotyping-of-pancreatic-patient-derived-organoids-100454345","NCT05196334","Pharmacotyping of Pancreatic Patient-derived Organoids","Pharmacotyping of Patient-derived Pancreatic Cancer Organoids From Endoscopic Ultrasound-guided Biopsy as a Tool for Predicting Oncological Response","Inclusion Criteria:\n\n* Signed informed consent\n* Histopathological confirmation of PDAC and planned standard first-line treatment prior to entering this study OR Patients suspected of primary locally advanced, non-metastatic PDAC based on cross-sectional imaging undergoing diagnostic standard of care (SOC) EUS-FNB procedure\n* Age \\> 18 years and older\n* Life expectancy greater than 3 months\n* ECOG\u002FWHO Performance Status (PS) 0-1\n* Patients must have normal organ and marrow function as defined below:\n* White blood cell count (WBC) ≥ 3 x 10⁹\u002FL\n* Platelet count ≥ 100 x 10⁹\u002FL\n* Serum bilirubin ≤1.5 x upper limit of normal (ULN) (patients with Gilbert's Syndrome must have a total bilirubin ≤ 50 mmol\u002FL)\n* PP ≥ 40 or INR ≤ 1.5\n* Serum creatinine ≤ 1.5 x ULN or CrCl ≥ 40 mL\u002Fmin (using the Cockcroft-Gault formula)\n\nExclusion Criteria:\n\n* Contraindications for nurse administered propofol sedation (NAPS)\n* Contraindications for EUS-FNB procedure",{"count":386,"type":21},88,"EUS-FNB samples will be used for organoid cultures, which will be co-cultured with cancer associated fibroblasts derived from the surrounding stroma of the lesion. The organoid cultures will be used for pharmacotyping using relevant chemotherapeutic agents used in the clinic, and the organoid's response compared with the patient's response.",[220],[390,391],"organoid","personalized medicine","2024-10-02",{"date":394,"type":33},"2024-10-03",{"date":396,"type":33},"2021-07-01",{"date":398,"type":21},"2025-08-31",{"name":39,"class":40},{"id":401,"slug":402,"hasResults":11,"nctId":403,"briefTitle":404,"officialTitle":405,"acronym":4,"eligibilityCriteria":406,"healthyVolunteers":11,"sex":18,"minAge":130,"maxAge":4,"enrollmentInfo":407,"targetDuration":4,"studyType":134,"phases":4,"briefSummary":409,"conditions":410,"keywords":4,"overallStatus":84,"whyStopped":4,"lastUpdateSubmitDate":414,"lastUpdatePostDateStruct":415,"startDateStruct":417,"completionDateStruct":419,"leadSponsor":421,"locationsCount":122},"100382897","exploring-pathogenesis-and-treatment-of-hypercalcemia-caused-by-intramuscular-injection-of-paraffinoil-100382897","NCT04265599","Exploring Pathogenesis and Treatment of Hypercalcemia Caused by Intramuscular Injection of Paraffinoil","Hypercalcemia After Cosmetic Paraffin Oil Injections: Unravelling Etiology, Pathogenesis and Potential Treatments","Inclusion Criteria:\n\n* previous intramuscular injection of paraffin or other oil\n\nExclusion Criteria:\n\n* none",{"count":408,"type":21},200,"The aim of the study is to characterize paraffin oil induced granulomatous disease. We will investigate pathogenesis and natural history of paraffin disease. Subsequently, through further translational studies, we intend to identify novel treatments to be tested in future randomized clinical trials.",[411,412,413],"Hypercalcemia","Renal Injury","Paraffinoma","2024-09-30",{"date":416,"type":33},"2024-10-01",{"date":418,"type":33},"2019-04-30",{"date":420,"type":21},"2027-01-31",{"name":39,"class":40},{"id":423,"slug":424,"hasResults":11,"nctId":425,"briefTitle":426,"officialTitle":426,"acronym":427,"eligibilityCriteria":428,"healthyVolunteers":11,"sex":18,"minAge":130,"maxAge":4,"enrollmentInfo":429,"targetDuration":4,"studyType":22,"phases":431,"briefSummary":433,"conditions":434,"keywords":4,"overallStatus":84,"whyStopped":4,"lastUpdateSubmitDate":436,"lastUpdatePostDateStruct":437,"startDateStruct":439,"completionDateStruct":441,"leadSponsor":443,"locationsCount":93},"100450354","phase-4-accelerated-treatment-of-endocarditis-100450354","NCT05144399","Accelerated Treatment of Endocarditis","POET II","Inclusion Criteria:\n\n* Admitted with left-sided infectious endocarditis (duke criteria)\n* \\\u003C 14 days of relevant antibiotic treatment for endocarditis\n* One of the following bacteria: Streptococci, enterococcus faecalis, staphylococcus aureus\n* \\> 18 years old\n\nExclusion Criteria:\n\n* Known immune incompetency,\n* Relapse endocarditis with 6 months,\n* Unable to give informed concent",{"count":430,"type":21},475,[432],"PHASE4","Existing guidelines recommend a duration of antibiotic treatment of endocarditis of 4-6 weeks one or more types of intravenously administered antibiotics. The long hospitalization increases several risks for the patient, including mental strain and increased loss of function. Furthermore, it poses a significant financial burden on the health systems. Current guidelines fail to use available clinical and paraclinical, data collected from patients (echo, temperature, CRP, leukocytes, procalcitonin etc.) to determine duration of treatment. A strategy including these data in treatment algorithms ensures an individualized treatment, targeting the individual patient's course and response to treatment. Thus, the purpose of this open-label, prospective, non-inferiority, RCT study is to investigate the safety and effectiveness of shortening treatment of endocarditis based on the individual patient's initial treatment response, sampling 475 patients, approx. 125 patients with each type of bacteria (Streptococci; Enterococcus faecalis; Staphylococcus aureus).",[435],"Endocarditis","2024-01-17",{"date":438,"type":33},"2024-01-18",{"date":440,"type":33},"2019-04-01",{"date":442,"type":21},"2026-12-31",{"name":39,"class":40},{"id":445,"slug":446,"hasResults":11,"nctId":447,"briefTitle":448,"officialTitle":449,"acronym":450,"eligibilityCriteria":451,"healthyVolunteers":11,"sex":18,"minAge":130,"maxAge":4,"enrollmentInfo":452,"targetDuration":4,"studyType":134,"phases":4,"briefSummary":454,"conditions":455,"keywords":459,"overallStatus":84,"whyStopped":4,"lastUpdateSubmitDate":463,"lastUpdatePostDateStruct":464,"startDateStruct":466,"completionDateStruct":468,"leadSponsor":470,"locationsCount":122},"100472972","re-optimization-based-online-adaptive-radiotherapy-of-anal-cancer-100472972","NCT05438836","Re-optimization Based Online Adaptive Radiotherapy of Anal Cancer","ROAR-A: Re-optimization Based Online Adaptive Radiotherapy of Anal Cancer","ROAR-A","Inclusion Criteria:\n\n* Biopsy-verified anal cancer\n* Eligible for curative intended radiotherapy\n* Written and oral consent\n\nExclusion Criteria:\n\n* Other malignant disease within the past 5 years (excluding basal cell carcinoma)",{"count":453,"type":21},205,"A single-arm, prospective, Phase II, single-center clinical trial that will investigate if daily online adaptive radiotherapy for anal cancer will significantly reduce early treatment-related GI toxicity compared with the historically reported rate for non-adaptive intensity modulated radiation therapy (IMRT).",[456,457,458],"Anal Cancer","Anal Carcinoma","Anal Squamous Cell Carcinoma",[460,461,462],"adaptive radiotherapy","Anal cancer","Online Adaptive radiotherapy (oART)","2023-09-21",{"date":465,"type":33},"2023-09-25",{"date":467,"type":33},"2022-01-01",{"date":469,"type":21},"2031-01-01",{"name":39,"class":40},{"id":472,"slug":473,"hasResults":11,"nctId":474,"briefTitle":475,"officialTitle":476,"acronym":477,"eligibilityCriteria":478,"healthyVolunteers":17,"sex":236,"minAge":130,"maxAge":4,"enrollmentInfo":479,"targetDuration":4,"studyType":134,"phases":4,"briefSummary":480,"conditions":481,"keywords":485,"overallStatus":84,"whyStopped":4,"lastUpdateSubmitDate":488,"lastUpdatePostDateStruct":489,"startDateStruct":491,"completionDateStruct":492,"leadSponsor":494,"locationsCount":122},"100518121","conservative-treatment-or-resuturing-among-women-with-perineal-wound-dehiscence-after-vaginal-labour-100518121","NCT06026423","Conservative Treatment or Resuturing Among Women With Perineal Wound Dehiscence After Vaginal Labour","Dehisced Perineal Tear After Vaginal Labour (HEAL) - Conservative Treatment or Resuturing","HEAL","Inclusion Criteria:\n\n* Women with a vaginal delivery who have had a primary repair of a second-degree perineal tear or episiotomy\n* At least 18 years old\n* Able to understand, read and speak Danish or English\n* Able to give informed consent\n\nExclusion Criteria:\n\n* None, first, third- and fourth-degree tear\n* Cesarean Section",{"count":162,"type":21},"The goal of this observational study is to make us more aware of the short and long-term outcomes for women having an uncomplicated healing process after a rupture or birth cut in the perineum after giving birth in relation to a healing process with a dehisced wound treated with conservative management or secondary suturing.\n\nParticipants will be asked to do\n\n* A gynecological examination at one month after birth and 9-12 months after birth.\n* Have a picture taken of the healing process\n* Answer a questionnaire at one month, three months, and 9-12 months after birth",[482,483,484],"Dehiscence Wound","Secondary Perineal Tear","Episiotomy; Dehiscence",[486,483,487],"Dehiscence","Episiotomy","2023-09-15",{"date":490,"type":33},"2023-09-18",{"date":488,"type":33},{"date":493,"type":21},"2026-09-01",{"name":39,"class":40},""]